ARCA aims to boost participation by easing stringent enrollment criteria in a study investigating Gencaro in heart failure patients with a favorable response genotype.
The FDA has approved a trial investigating bucindolol in approximately 3,200 chronic heart failure patients who have a genotype associated with response to the beta-blocker and mild vasodilator.
While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.
Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.
In Nature this week: paternal age associated with de novo mutations in children, and more.
Nature News writes that researchers are still wrangling over the role of the p-value.